John Davis - Artivion Senior Vice President - Global Sales and Marketing
| AORT Stock | USD 28.41 0.14 0.50% |
Insider
John Davis is Senior Vice President - Global Sales and Marketing of Artivion since 2015.
| Age | 59 |
| Tenure | 9 years |
| Address | 1655 Roberts Boulevard N.W., Kennesaw, GA, United States, 30144 |
| Phone | 770 419 3355 |
| Web | https://artivion.com |
Artivion Management Efficiency
The company has return on total asset (ROA) of 0.0229 % which means that it generated a profit of $0.0229 on every $100 spent on assets. This is way below average. Artivion's management efficiency ratios could be used to measure how well Artivion manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.08 in 2024. Return On Capital Employed is likely to drop to 0.01 in 2024. At this time, Artivion's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 832 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 43.7 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Branislav Vajdic | Heartbeam | 69 | |
| Suresh Venkatachari | Healthcare Triangle | 57 | |
| Denise Pufal | Nutex Health | N/A | |
| Kristi Lane | Healthcare Triangle | N/A | |
| Thyagarajan Ramachandran | Healthcare Triangle | 48 | |
| Jon Hunt | Heartbeam | 68 | |
| Jon Bates | Nutex Health | 54 | |
| MD MBA | Nutex Health | 51 | |
| Sudish Mogli | Healthcare Triangle | 55 | |
| Ryan Bond | Aclarion | 52 | |
| Daniel Tan | EUDA Health Holdings | 43 | |
| Michael Gill | Healthcare Triangle | 46 | |
| LaChoenda Rosales | Nutex Health | N/A | |
| Shibu Kizhakevilayil | Healthcare Triangle | 52 | |
| Richard Brounstein | Heartbeam | 74 | |
| Ken Persen | Heartbeam | N/A | |
| Wei Chen | EUDA Health Holdings | 39 | |
| Vivian MBA | Nutex Health | N/A | |
| Steven Sobak | EUDA Health Holdings | 78 | |
| John Lorbiecki | Aclarion | 61 | |
| Elizabeth Hall | Nutex Health | N/A | |
Management Performance
| Return On Equity | -0.0029 | ||||
| Return On Asset | 0.0229 |
Artivion Leadership Team
Elected by the shareholders, the Artivion's board of directors comprises two types of representatives: Artivion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Artivion. The board's role is to monitor Artivion's management team and ensure that shareholders' interests are well served. Artivion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Artivion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Bevevino, Independent Director | ||
| Jeffrey Burbank, Lead Independent Director | ||
| Jean Holloway, Senior Vice President Chief Compliance Officer, General Counsel, Secretary | ||
| Jon Salveson, Independent Director | ||
| Andrew Green, Vice President - Regulatory Affairs | ||
| Thomas Ackerman, Independent Director | ||
| Rochelle Maney, Vice President - Global Quality Assurance | ||
| Scott Capps, Vice President - Clinical Research | ||
| Marna Borgstrom, Independent Director | ||
| Matthew Getz, Vice President - Human Resources | ||
| James Bullock, Independent Director | ||
| Jean Esq, General VP | ||
| D Lee, Chief Financial Officer, Chief Operating Officer, Executive Vice President | ||
| CPA CPA, VP Officer | ||
| James Mackin, Chairman of the Board, President, Chief Executive Officer, Director | ||
| Anthony Semedo, Independent Director | ||
| Dennis Maier, Vice President - Operations | ||
| Joshua Wells, Sr Devel | ||
| Marshall Stanton, Senior Vice President Clinical Research and Chief Medical Officer | ||
| Marshall MD, Senior Officer | ||
| Robert Thomson, Vice Development | ||
| Amy CPA, VP Officer | ||
| Florian Tyrs, Vice Operations | ||
| Lance CPA, Executive CFO | ||
| F Barthold, Vice President - Research and Development | ||
| Amy Horton, Chief Accounting Officer, Vice President | ||
| John Davis, Senior Vice President - Global Sales and Marketing |
Artivion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Artivion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0029 | ||||
| Return On Asset | 0.0229 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 1.49 B | ||||
| Shares Outstanding | 41.92 M | ||||
| Shares Owned By Insiders | 5.51 % | ||||
| Shares Owned By Institutions | 87.09 % | ||||
| Number Of Shares Shorted | 3 M | ||||
| Price To Book | 3.89 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artivion Stock Analysis
When running Artivion's price analysis, check to measure Artivion's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artivion is operating at the current time. Most of Artivion's value examination focuses on studying past and present price action to predict the probability of Artivion's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artivion's price. Additionally, you may evaluate how the addition of Artivion to your portfolios can decrease your overall portfolio volatility.